Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Arcutis Biotherapeutics Inc. (ARQT:NASDAQ), powered by AI.
Arcutis Biotherapeutics Inc. is currently trading at $24.38. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Arcutis Biotherapeutics Inc. on Alpha Lenz.
Arcutis Biotherapeutics Inc.'s P/E ratio is -192.2.
“Arcutis Biotherapeutics Inc. trades at a P/E of -192.2 (undervalued) with modest ROE of -9.3%. 3Y revenue CAGR of 367.3% highlights clear growth momentum.”
Ask for details →Arcutis Biotherapeutics Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for dermatological diseases and conditions. Primarily focused on enhancing therapies for skin diseases, Arcutis aims to improve the standard of care in dermatology through the use of its proprietary technologies and formulation science expertise. The company addresses critical needs across a variety of dermatological disorders, including psoriasis, atopic dermatitis, and seborrheic dermatitis, by creating topical treatments that prioritize patient comfort and efficacy. Arcutis Biotherapeutics' pipeline is rich with investigational drugs that incorporate cutting-edge science to offer potential breakthroughs for millions of patients worldwide. The company's initiatives are crucial for the dermatology pharmaceutical sector as they strive to fill gaps in current treatments and provide alternative solutions with improved safety and effectiveness profiles. Positioned at the intersection of health and innovation, Arcutis operates out of its headquarters in Westlake Village, California. The company plays an influential role in advancing dermatological healthcare and is a key player in the niche yet significant field of pharmaceuticals focused on skin conditions.
“Arcutis Biotherapeutics Inc. trades at a P/E of -192.2 (undervalued) with modest ROE of -9.3%. 3Y revenue CAGR of 367.3% highlights clear growth momentum.”
Ask for details →Arcutis Biotherapeutics Inc. (ticker: ARQT) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 342 employees. Market cap is $3.1B.
The current price is $24.38 with a P/E ratio of -192.18x and P/B of 16.37x.
ROE is -9.30% and operating margin is -3.25%. Annual revenue is $376M.